RE: The Next Two Weeks19 Sep 2025 06:24
Roger65,
To deal with the points you have raised.
1)I do not see any reason why the publication of the implementation guide should be delayed yet further. Johnlay****'s source, if that source is to be believed, was quite clear that the implementation guidance will still progress and the likely timeline for publication would be mid to late September. Why, as you indicate, would we be getting news about news if the news was ready to be published? It has already been four and a half months since the pilot trial ended. The implementation may well be delayed but I doubt the guidance itself will be further delayed.
2)Yes, agreed, the RNS was selective and did not confirm the belief that implementation would immediately follow the publication of the guidance. Unfortunately we have been fed half truths for quite a while.
3)Hopefully the directors are not focused on eking out their salaries but on keeping the company going!
4)You offer no rationale as to why the guidance should be further delayed.
Another point that is often overlooked by the doom mongers is that there is revenue momentum. The revenue increased from £500k in the previous year to £1m for the last year. That should increase still further this financial year, according to the company, to the point of break even by the second half, ie by June 2026. There is revenue coming in from Peterborough City Hospital that has adopted CYP2C19, the 14 hospitals in the UK that have taken on board MTRNR1, from the Scottish rollout, and the company told us in the half year report that it expects continued revenue growth in 2026 "fuelled by international expansion and regulatory advance".
Where we are in full agreement is about the directors taking a pay cut. It is disgraceful that given the financial straits of the company the directors have not done that up to now. Earlier this week I again asked Walbrook to pass investors' feelings on that matter to the board.
AIMHO
Sign In
Follow the stocks
